"By improving the speed and precision of data curation, and with our use of AI, we ensure that clinical trial designs are based on the most accurate and relevant information and can dynamically identify eligible patients for trials in real time." Craig Serra, Flatiron's Head of Clinical Research Scientific and Technical Engagement, sat down with The Clinical Trial Vanguard to discuss how we're revolutionizing oncology #clinicaltrials through innovative tech that integrates #RWD and #RWE ⬇️ https://lnkd.in/eZ78KKZX
Flatiron Health
Biotechnology Research
New York, New York 75,947 followers
Reimagining the infrastructure of cancer care
About us
Flatiron Health’s mission is to improve and extend lives by learning from the experience of every person with cancer.
- Website
-
http://www.flatiron.com
External link for Flatiron Health
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- New York, New York
- Type
- Privately Held
Locations
-
Primary
233 Spring St
5th Floor
New York, New York 10013, US
Employees at Flatiron Health
-
Elia Brandao
-
Michelle Cadrin-Msumba
Solution Design Manager // Medical Practice Management // Revenue Cycle Management // Enabling sales with data and technology // On site Needs…
-
Rahul Bafna
Healthcare Technology Product Leader
-
Mariano Peterson
Engineering Leader in Platform, Cloud, and Infrastructure
Updates
-
What could #clinicalresearch teams do with more hours in their day? It’s been estimated that as much as 50% of data entry time in #clinicaltrials could be saved by using EHR to EDC connectors, which promise to remove duplicate data entry. Our latest research, published in the Journal of Clinical Oncology and presented at #ASCO24, sought to assess how EHR-to-EDC connectors like Flatiron Clinical Pipe™ can help reduce the burden of data entry and management in modern clinical trials. Hear from Ivy Altomare MD, Head of Research Oncology, and read our research in full on our website: http://spkl.io/60474CrRV
-
Join a panel of experts from AstraZeneca, University of Pennsylvania School of Medicine, and Regional Cancer Care Associates for an upcoming webinar on the state of breast cancer research today. Tune in for a discussion on: - How organizations across the healthcare industry are tackling complex clinical decision making - The use of #AI to accelerate #breastcancer research and clinical practice - Treatment selection, sequencing, and the increasingly critical role of genomic testing 📅 NEXT WEEK: Tues, July 23 12-1 PM ET Secure your spot & ask our panel of experts your questions directly. Register & submit questions now: http://spkl.io/60494Cr3V
-
In a recent episode of HIT Like a Girl Pod, CEO Carolyn Starrett sat down with host Joy Rios to discuss how Flatiron tackling some of the biggest challenges in oncology—from clinical trial inefficiencies to data fragmentation and silos. Carolyn shares how our tech is leveraging #AI and #machinelearning to: - Identify eligible patients for #clinicaltrials in real-time - Streamline data collection by automating transfers to trial databases - Make #RWE more actionable for researchers Listen to the full conversation to learn more about our work as we reimagine the infrastructure of cancer care: https://lnkd.in/eYcJQjSw
Data-Driven Healthcare: Transforming Cancer Care | Amplifying Women in Healthcare and Health IT
hitlikeagirlpod.com
-
Using systemic anti-cancer therapy (SACT) near end-of-life (EOL) is linked to negative outcomes, including increased hospitalization and costs. Despite recommendations to reduce chemotherapy within 14 days of death, national SACT rates in this period remain unchanged. Critics argue that EOL metrics might miss patients benefiting from aggressive treatment. In this #research published in JAMA Oncology, researchers from Yale Cancer Center, MD Anderson Cancer Center, and Flatiron Health explore if “aggressive” SACT use near EOL improved outcomes in advanced/metastatic cancer patients. This research challenges common EOL oncology practices and emphasizes the need to understand economic factors shaping treatment decision in the evolving landscape of EOL oncology care. Visit our website to learn more: http://spkl.io/604747xdL
Systemic anticancer therapy and overall survival in patients with very advanced solid tumors
resources.flatiron.com
-
TOMORROW: Hear from authors of recent JCO pub review their findings on EHR-to-EDC tech in trials, how it can reduce data management burden, & enhance overall efficiency. ⭐ “Utility of automated data transfer for cancer #clinicaltrials” 📅 Wednesday, July 17th at 11 AM https://lnkd.in/etmGFYAR
-
A new ISPOR report from Flatiron’s Blythe Adamson, PhD, MPH and other industry experts, provides actionable takeaways for standardizing the use of #RWD for #HTAs ⬇️ Introducing a framework and accompanying ISPOR SUITABILITY Checklist, this ISPOR Good Practices Report addresses the validity and relevance of EHR-derived #RWD to fill evidence gaps and improve decision-making. Visit our website for the full report and to learn more about why this matters ⬇️ http://spkl.io/604547xd7
-
“Meet patients where they’re at” is another way of speaking to the reduced burden we can expect when #clinicaltrials are designed pragmatically. Hear from Flatiron’s Director of Clinical Operations, Josh Buddle on the potential of post-marketing evidence generation. To learn why it’s critical to capitalize on this opportunity, watch the full episode with ResearchRevolution here: http://spkl.io/604147xe9
-
Hear from the authors of a recent JCO publication review their research findings on EHR-to-EDC technology in #clinicaltrials and how it can reduce data management burden and enhance overall efficiency. ⭐ "Utility of automated data transfer for cancer clinical trials” 📅 Wednesday, July 17th at 11 AM: http://spkl.io/604847xeK
-
#RWE and cross-industry collaborations are critical to driving innovative solutions that improve and extend the lives of people with #lungcancer. With 230,000 new cases of lung cancer a year in the United States, it remains one of the most active areas of #cancerresearch today. Flatiron’s VP of Evidence Client Solutions, Christine Hung, shared her perspective on opportunities for lung cancer research and three industry case studies where #RWE supported critical research across the biopharma lifecycle. Read more now: http://spkl.io/6043470af